|
 The two-dose candidate requires lower dosages than the injected
version and could help CanSinoBIO boost its production capacity, the
company's chief executive said in April.
Two inhaled doses of the Ad5-nCoV vaccine, given 28 days apart,
elicited similar level of neutralising antibodies to those of a
single injection, according to a peer-reviewed paper.
The readings are based on data from a Phase I trial involving 130
healthy adult participants in China and published on the medical
journal the Lancet Infectious Disease on Monday.
https://bit.ly/374v22L
The inhaled vaccine did not cause serious side effects in the study,
the paper said.
Some of the trial participants received the injectible version of
the vaccine followed by an inhaling booster 28 days later. The group
induced strong neutralizing antibody responses, the report said.
[to top of second column] |
 Authors of the paper includes researchers at
Academy of Military Medical Sciences, CanSino
Biologics, and other Chinese institutions.
The single-dose injected Ad5-nCoV vaccine is
already cleared for use in China, Mexico and
Pakistan.
(Refile to fix company name to CanSino
Biologics, not BioLogics)
(Reporting by Roxanne Liu and Ryan Woo, Editing
by Louise Heavens)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
 |
